Psychedelics Stocks Are Falling After a Shocking Vote at the FDA. Here's What You Need to Know. [Yahoo! Finance]
Mind Medicine (MindMed) Inc. - Common Shares (MNMD)
Company Research
Source: Yahoo! Finance
But none of those businesses have any of their medicines under consideration for approval by regulators. Nor did the FDA or anyone else in the federal government issue a ruling that said therapies derived from psychedelic molecules are prohibited. Here's what's going on and why it's likely to remain relevant for investors for at least the next couple of years. What went wrong? Despite many psychedelic drug candidates in clinical trials right now, there aren't yet any psychedelic medicines on the market since they have been subject to prohibition as a class for quite some time. Lykos Therapeutics, a public benefit company (PBC), sought to change that by being the first player to commercialize its MDMA-based therapy for post-traumatic stress disorder (PTSD). If you're not familiar, MDMA is known by the street names ecstasy or molly, and while still a Schedule I drug, psychedelic drug biotechs looking into its promise in addressing difficult-to-treat mental illnesses. The conce
Show less
Read more
Impact Snapshot
Event Time:
MNMD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MNMD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MNMD alerts
High impacting Mind Medicine (MindMed) Inc. - Common Shares news events
Weekly update
A roundup of the hottest topics
MNMD
News
- Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.MarketBeat
- MindMed to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual ConferenceBusiness Wire
- MindMed Announces Constructive End-of-Phase 2 Meeting with U.S. FDA for MM120 in Generalized Anxiety Disorder (GAD)Business Wire
- Mind Medicine (MindMed) Inc.'s (NASDAQ:MNMD) 18% loss last week hit both individual investors who own 46% as well as institutions [Yahoo! Finance]Yahoo! Finance
- Wall Street Lunch: Not An Ecstatic Day [Seeking Alpha]Seeking Alpha
MNMD
Earnings
- 5/8/24 - Miss
MNMD
Sec Filings
- 6/25/24 - Form 4
- 6/25/24 - Form 4
- 6/25/24 - Form 4
- MNMD's page on the SEC website